Vanguard Capital Management’s Attovia Therapeutics ATTO Stock Holding History

Vanguard Capital Management’s Portfolio ATTO Stock Details ATTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.4M	Buy	+782,012	New	+$16.5M	﹤0.01%	2601

Other funds holding ATTO

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $132M AUM 92.09% 1-Year Est. Return

Vanguard Capital Management's ATTO Position: Q3 2026 in Review

Vanguard Capital Management opened a new position in Attovia Therapeutics (ATTO) in Q3 2026: 782,012 shares worth $13.4M. The stake represents ﹤0.01% of the portfolio and ranks #2601 among its holdings.

27 funds tracked by Wall St. Rank hold ATTO as of Q3 2026.

Vanguard Capital Management held 782,012 shares of Attovia Therapeutics worth $13.4M as of Q3 2026.
Attovia Therapeutics was a new Vanguard Capital Management position in Q3 2026.
Attovia Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2601 holding.
27 funds tracked by Wall St. Rank held Attovia Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.